If you are not happy with the results below please do another search
The U.S. Food and Drug Administration granted approval for the commercialization of Eli Lilly and Company and Incyte Corporation’s Olumiant (baricitinib), setting a precedent for COVID-19 treatments.
Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable, more efficacious vaccine is needed, but what should it be? The scientific community has not reached a consensus, according to BioSpace.
The Institute for Clinical and Economic Review recommended two out of three outpatient treatments for COVID-19 in the market, singling out molnupiravir as having inadequate evidence to support claims that it is better than symptomatic care.
AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).
Moderna Inc. Chief Financial Officer Jorge Gomez departed a day after taking charge, the vaccine maker said on May 11, following his former employer disclosing an internal probe related to financial reporting.
Development of a new cancer treatment pioneered by Roche was thrown into doubt on May 11 when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s shares.
As Paxlovid has become more widely used, some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement.
Johnson & Johnson on May 11 appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of 2023.
A study published in Nature Communications describes how researchers at the United Kingdom Research Institute at the University of Cambridge stumbled upon a potential target of dementia research.
Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.